INTRODUCTION

5-ALA fluorescence-guided surgery of CNS tumors
The recent Food and Drug Administration (FDA) approval of 5-ALA (5-aminovelulinic acid; Gleolan ® ; photonamic GmbH & Co. KG) for use as an intraoperative optical imaging agent in patients with suspected high-grade gliomas (HGGs) in 2017 catapulted fluorescence-guided surgery (FGS) as a new standard for neurosurgeons and their patients in the United States (US) [1] . This would be the first ever optical imaging agent or tool approved for use in neurosurgery in the US. Over 20 years have passed since the initial patient series by Dr. Walter Stummer describing the use of 5-ALA to help neurosurgeons identify HGGs in the surgical field [2] . A landmark multicenter, phase III randomized trial completed 13 years ago confirmed that surgeons using 5-ALA FGS as a surgical adjunct could achieve more complete resections of tumors in HGG patients and better patient outcomes than with conventional microsurgery [3] .
The field of 5-ALA FGS has now been accepted globally with over 300 papers published as of 2018. With any new technology or tool used in neurosurgery, rigorous scientific analyses are required to understand the indication and limits of that technology/tool. Furthermore, combining established tools/technologies in neurosurgery with 5-ALA FGS needs to be assessed as well. In this Special Issue of the Journal of Neuro-Oncology, we have compiled the latest manuscripts by leaders in the field focusing on current applications of 5-ALA. We begin the Special Issue by focusing on the journey to FDA approval of 5-ALA for glioma surgery so that future technologies and tools can learn from the winding regulatory path that was taken for ultimate approval. We would like to thank all the manuscript authors and reviewers for providing high quality manuscripts to our Special Issue on 5-ALA FGS of CNS tumors. We believe that this will be an important contribution to the literature.
